REG - BkofA Merrill Lynch Horizon Therapeutics - 20230825_HORIZON THERAPEUTICS PLC_38.5(b)_IE_BOFAS

AmgenAnnouncement

29/08/2023 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc5400Ka&default-theme=true

RNS Number : 5400K  Bank of America Merrill Lynch  28 August 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             BofA Securities, Inc.
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             25/08/2023

BofA Securities, Inc.

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

25/08/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long             Short
                                                Number   %       Number   %
 (1)  Relevant securities                       213,158  0.093%  110,101  0.048 %
 (2)  Derivatives (other than options):         172,283  0.075%  71,336   0.031%
 (3)  Options and agreements to purchase/sell:  40,000   0.017%  29,500   0.013%
 Total                                          425,441  0.186%  210,937  0.092%

213,158

0.093%

110,101

0.048 %

 (2)  Derivatives (other than options):

172,283

0.075%

71,336

0.031%

 (3)  Options and agreements to purchase/sell:

40,000

0.017%

29,500

0.013%

Total

425,441

0.186%

210,937

0.092%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase       106                            106.3 USD
 Purchase       795                            106.32 USD
 Purchase       105                            106.33 USD
 Purchase       6                              106.39 USD
 Purchase       1                              106.44 USD
 Purchase       12                             106.46 USD
 Purchase       100                            106.485 USD
 Purchase       1,901                          106.5 USD
 Purchase       6                              106.54 USD
 Purchase       46                             106.56 USD
 Purchase       24                             106.58 USD
 Purchase       4,955                          106.67 USD
 Purchase       520                            106.67 USD

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale           100                            106.35 USD
 Sale           223                            106.36 USD
 Sale           502                            106.37 USD
 Sale           100                            106.375 USD
 Sale           50                             106.38 USD
 Sale           100                            106.39 USD
 Sale           103                            106.4 USD
 Sale           201                            106.41 USD
 Sale           1                              106.43 USD
 Sale           212                            106.44 USD
 Sale           1                              106.46 USD
 Sale           123                            106.48 USD
 Sale           102                            106.5 USD
 Sale           100                            106.51 USD
 Sale           1,510                          106.55 USD
 Sale           100                            106.555 USD
 Sale           1,441                          106.56 USD
 Sale           200                            106.565 USD
 Sale           312                            106.57 USD
 Sale           5                              106.58 USD
 Sale           20                             106.62 USD
 Sale           10                             106.63 USD
 Sale           22                             106.66 USD
 Sale           799                            107.5 USD
 Sale           601                            107.54 USD
 Sale           100                            107.55 USD
 Sale           100                            107.555 USD
 Sale           400                            107.56 USD
 Sale           70                             106.67 USD

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction     Number of relevant securities  Price per unit

e.g. CFD
(Note 5)                 (Note 6)
(Note 4)
 Swaps          Reducing a Long Position  4,952                          106.67 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details  Price per unit
 (Note 7)
(if applicable) (Note 4)
 N/A                    N/A      N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            28/08/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 996 6418
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPEAEPPAENDEFA